We propose that fucoxanthin’s FLT3-independent targeting of AKT-driven metabolic vulnerabilities may represent a novel strategy to circumvent the intrinsic resistance pathways in FLT3-ITD AML. This evidence concerns the gene AKT1 and acute myeloid leukemia.